Zobrazeno 1 - 3
of 3
pro vyhledávání: '"How, S Hin"'
Publikováno v:
Proceedings of Singapore Healthcare, Vol 31 (2022)
Osimertinib is a third-generation thyroxine kinase inhibitor (TKI) used in treating advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutation. Osimertinib is used as a second line treatment for patient
Externí odkaz:
https://doaj.org/article/a3bb8b3e473b499e9ee4bde99f202de4
Autor:
Egbert F Smit, Christophe Dooms, Jo Raskin, Ernest Nadal, Lye M Tho, Xiuning Le, Julien Mazieres, How S Hin, Masahire Morise, Viola W Zhu, Daniel Tan, Kristina H Holmberg, Barbara Ellers-Lenz, Svenja Adrian, Sabine Brutlach, Karl M Schumacher, Niki Karachaliou, Yi-Long Wu
Publikováno v:
Future Oncology. 18:1039-1054
MET amplification (METamp), a mechanism of acquired resistance to EGFR tyrosine kinase inhibitors, occurs in up to 30% of patients with non-small-cell lung cancer (NSCLC) progressing on first-line osimertinib. Combining osimertinib with a MET inhibit
Autor:
Egbert, F Smit, Christophe, Dooms, Jo, Raskin, Ernest, Nadal, Lye M, Tho, Xiuning, Le, Julien, Mazieres, How, S Hin, Masahire, Morise, Viola, W Zhu, Daniel, Tan, Kristina, H Holmberg, Barbara, Ellers-Lenz, Svenja, Adrian, Sabine, Brutlach, Karl M, Schumacher, Niki, Karachaliou, Yi-Long, Wu
Publikováno v:
Future oncology (London, England). 18(9)
Osimertinib is used to treat a type of lung cancer that has specific changes (mutations) in a gene called